Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07288567) titled 'A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents' on Dec. 16, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Bristol-Myers Squibb
Condition:
Schizophrenia
Intervention:
Drug: KarXT
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: January 27, 2026
Target Sample Size: 166
Countries of Recruitment:
United States
Colombia
Japan
Romania
Co...